Introduction {#Sec1}
============

Osteonecrosis of the femoral head (ONFH) is a common debilitating disease that occurs in young and middle-aged adults^[@CR1],[@CR2]^. In fact, children also suffer from ONFH with an incidence of 8.5--21 per 100 000, but in this population, it is called Perthes disease^[@CR3],[@CR4]^. Although the progressions of adult ONFH and Perthes disease differ, both conditions result in femoral head deformity or collapse. Therefore, preventing femoral head collapse is a significant treatment goal^[@CR5],[@CR6]^. The pathogenesis of ONFH remains unclear, but an imbalance of bone metabolism is considered one of the most important causes^[@CR7]^. When ONFH occurs, bone formation fails to keep pace with bone resorption, resulting in low bone mineral density in the femoral head and the progression to collapse^[@CR8]^. Therefore, clinicians must take measures to reduce bone resorption and improve osteogenesis when treating ONFH.

Bisphosphonates are a class of drugs that can bind to the bone and inhibit osteoclast activity by reducing bone resorption^[@CR9]--[@CR11]^. They are usually used to treat diseases involving bone resorption progression, such as osteoporosis, Paget's disease, and fibrous dysplasia^[@CR11]--[@CR13]^. Bisphosphonates has also been considered a promising medication for early ONFH and preventing femoral head collapse^[@CR14]--[@CR17]^. However, the efficiency of this kind of drug in both animal studies^[@CR18],[@CR19]^ and clinical trials^[@CR20],[@CR21]^ remains controversial. Furthermore, a meta-analysis of a small number of clinical studies reported that the use of bisphosphonates cannot prevent femoral head collapse or delay total hip replacement after ONFH^[@CR22]^. Consequently, the use of bisphosphonates in the early stage of ONFH seems to involve some challenges.

To evaluate the effect of bisphosphonates on preventing femoral head collapse after osteonecrosis, we identified all related animal studies and clinical trials from the electronic database and conducted this meta-analysis comprehensively to judge whether bisphosphonates should be recommended to ONFH patients and are worthy of further study.

Materials and Methods {#Sec2}
=====================

This meta-analysis conformed to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement^[@CR23]^.

Search strategy {#Sec3}
---------------

The study's search protocol was developed on December 20, 2016. An electronic search was conducted online to identify relevant studies published up to January 2017 in PubMed; Ovid MEDLINE(R) (1946 to present with daily update); all EBM reviews; the ISI Web of Science; Academic Search Premier, and MEDLINE in EBSCO; Cochrane Library databases; CBM; and CNKI databases using the following terms: (ibandronate or alendronate or bisphosphonate or zoledronate or pamidronate or clodronate) AND (osteonecrosis of the femoral head or femoral head necrosis or Perthes disease) in all fields. In addition, the reference lists of the retrieved articles were manually searched for further pertinent studies. Furthermore, we contacted the study authors for the raw data and to complete the search strategy whenever possible. The two investigators independently selected potential eligible studies and any discrepancy between them was resolved by consensus.

Data extraction {#Sec4}
---------------

The data collection was conducted by two investigators independently and the result was checked by a third investigator. Discrepancies were settled by group discussion. Collected data included the first author's surname, publication year, study location, study design, sample size, type of medicine or dose range, and route of medication delivery. For the animal studies, we extracted the characteristics of the animal models including species, animal age, weight, and sex; and outcomes including mean epiphyseal quotients (EQ), trabecular bone volume (BV), trabecular separation (TS), trabecular thickness (TT), and trabecular number (TN). When various methods were presented and more than two groups were analyzed in a single study, the data were assessed as two comparisons of those exposed to bisphosphonates if necessary. For clinical trials, we recorded pain scores, Harris scores, and femoral head collapse and THA occurrence rates.

Assessment of methodological quality {#Sec5}
------------------------------------

Two reviewers independently assessed the methodology of the included animal studies using updated Stroke Therapy Academic Industry Roundtable recommendations^[@CR24]^ and that of the clinic studies using the modified Jadad scale^[@CR25]^. The methodological quality of each individual study was scored against the following criteria: sample size calculation; inclusion and exclusion criteria; randomization; allocation concealment; reporting of objects excluded from the analysis; blinded assessment of the outcomes; and report of potential conflicts of interest and study funding. Each item was allocated one point for a quantitative appraisal of overall quality of the individual studies. Each animal study was given a quality score out of a possible total of seven points and the group median was calculated. The modified Jadad scale evaluated the clinical studies in terms of randomization (2 points); concealment of allocation (2 points); double blinding (2 points); and total withdrawals and dropouts (1 point). Clinical studies achieving a score of \>4 points were considered of high quality.

Statistical analysis {#Sec6}
--------------------

This meta-analysis was conducted using Review Manager Software (Revman 5.3, Cochrane Collaboration, Oxford, United Kingdom). For the animal studies, we divided them into Perthes model and mature ONFH model subgroups and analyzed the pooled results. The relative risk (RR) was used to measure the dichotomous outcomes, while the mean difference (MD) was used to analyze continuous outcomes, both with 95% confidence intervals (CI). When the parameter was measured using different methods, standard mean difference (SMD) was used to compare continuous outcomes (e.g. BV, TT, TN, and TS). Chi squared tests and the I^2^ statistic were used to evaluate statistical heterogeneity. An I^2^ \> 50% was considered to indicate significantly statistical heterogeneity and the random-effect or fixed-effect model was used. Publication bias was visually examined using funnel plots. Values of P \< 0.05 were considered statistically significant. The sensitivity analysis was performed to explore the impact of an individual study by the exclusion of one study each time. Publication bias was visually examined using funnel plots.

Results {#Sec7}
=======

Search results and study characteristics {#Sec8}
----------------------------------------

As shown in Fig. [1](#Fig1){ref-type="fig"}, a total of 508 potentially relevant articles were identified from the databases. Of them, 279 were screened. After a title and abstract screen, 230 were excluded. A total of 49 full-text articles were assessed for eligibility, but 26 were excluded for different reasons (10 review articles, eight studies lacked a control group, and data for eight studies were unavailable). The remaining 23 articles including 16 animal studies^[@CR16]--[@CR19],[@CR26]--[@CR37]^ and seven human studies^[@CR14],[@CR15],[@CR20],[@CR21],[@CR38]--[@CR40]^ were passed for synthetic evaluation for this meta-analysis. A summary of selected studies is shown in Table [1](#Tab1){ref-type="table"}, while the basic techniques of the included studies are shown in Table [2](#Tab2){ref-type="table"}. As Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} present, the median quality score of the reported animal studies was 4 (range, 3--6), while the median of modified Jadad score of the clinical studies was 5 (range, 4--7).Figure 1Flow chart of study selection.Table 1Summary of the basic information.**AuthorYearCountryStudy ObjectSG (n/hip)AgeSex,M/FCG (n/hip)AgeSex,M/F**Animal studiesKim HK(1)2005USApiglet84--5 wmale84--5 wmaleAya-ay J2007Germanypiglet56--9 wmale46--9 wmaleVandermeer JS2011USApiglet56--8 wmale56--8 wmaleKim HK (2)2014USApiglet66--8 wmale66--8 wmaleCheng TL2014Australiapiglet46--8 wmale46--8 wmaleZou Y2015USApiglet62--3 wmale92--3 wmaleAruwajoye OO2016USAPiglet105--8 wmale105--8 wMaleLittle DG(1)2003AustraliaRat1614 wfemale814 wFemaleLittle DG(2)2005AustraliaRat324 wfemale164 wFemaleFan M2012ChinaRat8NRmale8NRMaleXu XL2015ChinaRat108 wmale108 wmaleHofstaetter JG2009USARabbit1510--12 mmale1510--12 mMaleXu XL2015ChinaRat108 wmale108 wmaleXie XW2013ChinaRat308 wunlimited308 wunlimitedTan G2013ChinaRat608 wunlimited608 wunlimitedXin DS(1)2014ChinaRat15NRmale15NRmaleXin DS(2)2014ChinaRat15NRmale15NRmaleClinical studiesWang CJ2008TaiwanHuman23/3035.7 ± 4.7y13/1025/3038.6 ± 12.6y20/5Chen CH2012TaiwanHuman26/3248.4 ± 11.4y22/426/3344.2 ± 9.2y19/7Nishii T2006JapanHuman14/2048y07/7Aug-1336y07/1Lai KA2005TaiwanHuman20/2942.6yNR20/2542.4yNRLee YK2015KoreaHuman55/5543.8 ± 11.8y39/155/5545.2 ± 11.6y41/1Kang P2012ChinaHuman39/5543.8y640/5245.3y4Gao yan2016ChinaHuman32/3223--55y37/1832/3223--55y35/1721/1122/10SG: study group or bisphosphonates group; CG: control group. unlimited means animal gender is not limited. n/hip: animal number/hip number. w- weeks. y: years old. m: month. NR: not report.Table 2Detail information of the research technique.**AuthorKind of ONFHStudy designDrug deliveryDosageStudy period**Animal studiesKim HK(1)TraumaticIbandronate VS placeboSubcutaneous44.4 μg/kg,3 × per/w  × 6 w8 weeksAya-ay JTraumaticIbandronate VS placebointraosseous0.28 mg or 0.56 mg, once7 weeksVandermeer JSTraumaticIbandronate VS placebointraosseous0.56 mg, once8 weeksKim HK (2)TraumaticIbandronate+BMP VS BMPintraosseous0.6 mg, once8 weeksCheng TLTraumaticZoledronic+BMP VS BMPintraosseous0.25 mg, once8 weeksZou YTraumaticClodronate VS placebo Clodronate + Sim VS SimIntraosseous2.2 mg, once6 weeksAruwajoye OOTraumaticIbandronate VS placebo BMP+Ibandronate VS BMP Zoledronic acid VS placeboIntraosseous0.6 mg, once8 weeksLittle DG(1)TraumaticZoledronic acid VS placeboSubcutaneous0.1 mg/kg/w × 3 w6 weeksLittle DG(2)TraumaticZoledronic acid VS placeboSubcutaneous0.15 mg/kg in total15 weeksFan MTraumaticPLGA+zoledronate VS PLGASubcutaneous0.1 mg/kg,once5 weeksXu XLTraumaticAlendronate VS placeboImplanted30 μg, once6 weeksHofstaetter JGTraumaticalendronate+Lova VS LovaSubcutaneous150 μg/kg, 3 × per/w × 2 w24 weeksXie XWSteroidalendronate VS controlOral150 μg/(kg.d) × 4 w12 weeksTan GSteroidalendronate VS controlOral150 μg/(kg.d) × 4 w12 weeksXin DS(1)Traumaticalendronate VS controlIntragastric1 mg/(kg.d) × 2 w5 weeksXin DS(2)Traumaticalendronate VS controlIntragastric1 mg/(kg.d) 2 w5 weeksClinical studiesWang CJAlcohol, steroidESWT+alendronate VS ESWTOral70 mg/w for 1 year25 monthsChen CHAlcohol, steroidAlendronate +Ca+vitD VS Ca+vit DOral70 mg/w for 2 year24 monthsNishii TAlcohol,steroid, IdiopathicAlendronate VS placeboOral5 mg/day for 1 year12 monthsLai KAAlcohol,steroid, IdiopathicAlendronate VS placeboOral70 mg/w for 25 week24 monthsLee YKAlcohol,steroid, IdiopathicZoledronate+Ca+vitD VS Placebo+Ca+vit DIntravenous5 mg/year for 2 year24 monthsKang PAlcohol,steroid, IdiopathicAlendronate+MD+Ca+vitD VS PlaceboMD+Ca+vit DOral10 mg/day or 70 mg/w for 24 weeks63 monthsGao Ysteroidalendronate+Ca VS placebo +CaOral70 mg/week for 6 month6 monthsBMP: Bone Morphogenetic Protein; PLGA: Poly (lactic-co-glycolic acid); sim: Simvastatin; Lova: Lovastatin; ESWT: extracorporeal shockwave therapy.Table 3The methodological quality of individual study.**Authors(1)(2)(3)(4)(5)(6)(7)Total score**Animal studiesKim HK(1)\*\*\*\*4Aya-ay J\*\*\*\*4Vandermeer JS\*\*\*3Kim HK (2)\*\*\*\*4Cheng TL\*\*\*\*\*5Zou Y\*\*\*\*4Aruwajoye OO\*\*\*\*4Little DG(1)\*\*\*\*4Little DG(2)\*\*\*\*4Fan M\*\*\*\*\*5Xu XL\*\*\*\*4Hofstaetter JG\*\*\*\*4Xie XW\*\*\*\*4Tan G\*\*\*\*4Xin DS(1)\*\*\*\*4Xin DS(2)\*\*\*\*4\*One score means the studies fulfilling one of the criteria of (1) sample size calculation; (2) inclusion and exclusion criteria; (3) randomisation; (4) allocation concealment; (5) reporting of objects excluded from analysis; (6) blinded assessment; (7) reporting potential conflicts of interest and study funding.Table 4Modified Jadad Score for clinical trials.StudyRandomizationConcealment of allocationDouble blindingTotal Withdrawals and dropoutsTotalWang CJ**\*\*\*\*\***5Chen CH**\*\*\*\*\*\*\***7Nishii T**\*\*\*\***4Lai KA**\*\*\*\*\***5Lee YK**\*\*\*\*\*\*\***7Kang P**\*\*\*\*\*\***6Gao Y**\*\*\*\*\***5Each asterisk represents one point. Modified Jadad score is used to evaluate the quality of articles and studies achieving a score of ≥4 points were considered to be of high quality.

Primary analysis of animal studies {#Sec9}
----------------------------------

### Evaluation of femoral head sphericity {#Sec10}

Outcome evaluation and measurement methods are shown in Table [5](#Tab5){ref-type="table"}. We found that the included animal studies recorded similar outcomes in the summary. Sphericity measurements of the femoral head were derived using a modified EQ, which indicated the height at the center of the femoral head over the width. Seven studies of 118 Perthes disease animal models recorded the EQ, which was significantly increased in the experimental group using bisphosphonates compared with the control group (MD = 11.86; 95% CI, 4.60--19.12; Fig. [2](#Fig2){ref-type="fig"}). Five studies of a mature ONFH model recorded the EQ, and the result indicated that the bisphosphonates treatment had better outcomes (MD = 20.13; 95% CI, 11.17--29.10; Fig. [2](#Fig2){ref-type="fig"}). The pooled results of the two animal models were also significantly better in the experimental group (MD = 15.32; 95% CI, 9.25--21.39; Fig. [2](#Fig2){ref-type="fig"}).Table 5Outcome evaluation and measurement method of animal studies.StudyOutcome evaluationMeasurement methodAnimal studiesKim HK(1)EQX RadiographsTrabecular parameters (BV,TT,TN,TS)HistomorphometryAya-ay JEQX RadiographsTrabecular parameters (BV,TT,TN,TS)HistomorphometryVandermeer JSEQX RadiographsTrabecular parameters (BV,TT,TN,TS)HistomorphometryKim HK (2)EQX RadiographsTrabecular parameters (BV,TT,TN,TS)HistomorphometryCheng TLEQX RadiographsZou YEQX RadiographsTrabecular parameters (BV,TT)Micro-Quantitative-CTAruwajoye OOTrabecular parameters (BV)HistomorphometryLittle DG(1)Trabecular parameters (BV,TT,TN)HistomorphometryLittle DG(2)EQX RadiographsTrabecular parameters (BV,TT,TN)HistomomhometrvFan MEQX RadiographsTrabecular parameters (BV,TT,TS)Micro-Quantitative-CTXu XLEQX RadiographsTrabecular parameters (BV,TT,TS)HistomorphometryHofstaetter JGEQMicro- CT imageTrabecular parameters (TT)Micro-Quantitative-CTXie XWTrabecular parameters (TT,TN,TS)Micro-Quantitative-CTTan GTrabecular parameters (TT,TN,TS)Micro-Quantitative-CTXin DS(1)EQX RadiographsTrabecular parameters (BV,TT,TN,TS)Micro-Quantitative-CTXin DS(2)EQX RadiographsTrabecular parameters (BV,TT,TN,TS)Micro-Quantitative-CTEQ: Epiphyseal quotients; BV: bone volume; TT: Trabecular thickness; TN: trabecular number; TS: Trabecular separation.Figure 2Forest plot showing Epiphyseal quotient.

### Parametric analysis of bone trabeculae {#Sec11}

Trabecular bone volume (BV/TV) was presented in seven articles involving 190 animals with Perthes disease, and this meta-analysis demonstrated that animals in the bisphosphonate group had greater BV improvement (MD = 1.00; 95% CI, 0.55--1.45). Five studies of 120 mature ONFH models showed better BV/TV performance in the experimental group (SMD = 2.58; 95% CI, 1.27--3.88). The pooled outcomes were also higher in the bisphosphonate group (SMD = 1.57; 95% CI, 0.94--2.20) (Fig. [3](#Fig3){ref-type="fig"}).Figure 3Forest plot showing bone volume.

There were five studies with 95 Perthes disease models (SMD = 1.46; 95% CI, 0.51--2.40) and five studies of 264 mature ONFH models (SMD = 1.20; 95% CI, 0.59--1.80) showed the TN in this meta-analysis, and according to the pooled outcomes, the experimental group was superior to the control group (SMD = 1.30; 95% CI, 0.80--1.79; Fig. [4](#Fig4){ref-type="fig"}). Six studies of 110 Perthes disease models (SMD = 0.61; 95% CI, −0.54--1.76) and another eight studies of 330 mature ONFH models (SMD = 0.91; 95% CI, 0.06--1.76) analyzed the trabecular thickness and reported significantly better results in the bisphosphonate group (SMD = 0.77; 95% CI, 0.10--1.43; Fig. [5](#Fig5){ref-type="fig"}). At the same time, four articles examining 47 Perthes disease models (SMD = −0.79; 95% CI, −1.40 to −0.18) and six studies of 276 mature ONFH models (SMD = −1.32; 95% CI, −2.08 to −0.56) showed that the bisphosphonates improved the trabecular separation (SMD = −1.14; 95% CI, −1.70 to −0.58; Fig. [6](#Fig6){ref-type="fig"}).Figure 4Forest plot showing trabecluar number.Figure 5Forest plot showing trabecular thickness.Figure 6Forest plot showing trabecular separation.

### Outcomes of clinical trials {#Sec12}

The pooled results of pain score with four studies of 277 patients and the hip Harris scores from five studies of 329 patients showed that bisphosphonate use achieved better pain scores (SMD = −0.20; 95% CI, −0.43--0.04; Fig. [7](#Fig7){ref-type="fig"}) and higher Harris scores (MD = 6.51; 95% CI, −2.76--5.78; Fig. [8](#Fig8){ref-type="fig"}); however, the differences were not statistically significant (p = 0.10 and p = 0.17, respectively). At the same time, the overall estimated proportion of patients who experienced progression to collapse in six studies involving 420 cases seemed to be reduced by bisphosphonate therapy (RR = 0.55; 95% CI, 0.26--1.16; Fig. [9](#Fig9){ref-type="fig"}), but it no significant difference was noted (p = 0.12). Likewise, the THA incidence tended to improve in patients treated with bisphosphonates (RR = 0.55; 95% CI, 0.28--1.09; Fig. [10](#Fig10){ref-type="fig"}), but the difference was not statistically significant (p = 0.09).Figure 7Forest plot showing pain score.Figure 8Forest plot showing Harris score.Figure 9Forest plot showing collapse of the femoral head.Figure 10Forest plot showing patients undergoing total hip arthroplasty.

Discussion {#Sec13}
==========

This meta-analysis aimed to determine whether bisphosphonates exerted effects on preventing femoral head collapse after osteonecrosis in animal models or clinical trials. Our results showed that bisphosphonate use significantly improved EQ indicative of femoral head sphericity as well as better BV, TN, trabecular separation, and trabecular thickness in the animal model. Unexpectedly, this finding is not supported by clinical studies, which showed no statistically significant differences in pain improvement, complications, or the need for THR. The animal studies and clinical trials seemed to present discordant outcomes.

There is a balance between osteoblast and osteoclast activity in the repair of ONFH 8^[@CR41],[@CR42]^. Osteoblasts are responsible for new bone formation, while osteoclasts are the bone resorptive cells. Although removal of the dead bone is also beneficial to the body, an excessively increased resorption rate leads to femoral head deformity and collapse. Some researchers have found that the osteoclasts become more active and develop a longer lifespan in the presence of osteonecrosis^[@CR43],[@CR44]^. This may be the cause of the imbalance between osteogenesis and bone resorption. Bisphosphonates suppress the HMG-CoA reductase pathway and then inhibit osteoclast-mediated bone resorption, both of which accelerate osteoclast death^[@CR32]^.

Although many animal studies^[@CR16],[@CR17],[@CR27]^ and clinical trials^[@CR14],[@CR15]^ have proven the efficiency of bisphosphonates in the treatment of ONFH, other researchers maintain different opinions. In clinical studies, Lee YK, *et al*. used zoledronate to treat patients with Steinberg stage I or II ONFH with a medium to large necrotic area, but their outcomes show that zoledronate does not prevent collapse of the femoral head or reduce the need for total hip arthroplasty^[@CR39]^. Chen CH, *et al*. conducted a multicenter, prospective, randomized, double-blind, placebo-controlled study using alendronate to prevent femoral head collapse but concluded that alendronate had no obvious effects on decreasing the need for THA and cannot reduce disease progression or improve quality of life^[@CR21]^. Moreover, the animal studies of Aruwajoye OO, *et al*.^[@CR19]^ and Zou Y, *et al*.^[@CR18]^ showed that the use of ibandronate alone did not obviously improve osteonecrosis, while the combination of ibandronate and other drugs such as BMP-2 or simvastatin could exert better protective effects. Likewise, Fan, *et al*.^[@CR30]^ demonstrated that zoledronate could inhibit the formation of new vasculature, which may not benefit the repair process of ONFH. Accordingly, the current data was in controversy on the effectiveness of bisphosphonates.

Based on the outcomes of this meta-analysis, we found the EQ that stands for the height at center of the femoral head over the width, which used to evaluate the femoral head sphericity, was improved in the bisphosphonate group. This means that the using of bisphosphonates indeed exert effects on protecting the femoral head morphology. At the same time, the BV, TN, trabecular thickness, and trabecular separation factors used to assess bone mass of the femoral head in the animal model were all significantly improved by bisphosphonate use, a finding that was very encouraging. These results indicated that controlling the pathological activity of the osteoclasts helped repair the ONFH^[@CR30]^. At the same time, some other studies^[@CR17],[@CR45]^ reported that inhibiting osteoclast activity would help increase osteoblast action and, in turn, lead to a positive balance of bone formation. Resorption of dead compact bone during osteonecrosis repair may decrease the structural properties and mechanical support of the femoral head and may be partially responsible for the collapse in the late stages of osteonecrosis^[@CR17],[@CR45]^. Thus, intervening in this process with bisphosphonates would make some difference just as our results showed. However, we also realized that those encouraging outcomes were drawn from the heterogeneous methods/models. Animal models of ONFH or Perthes disease are still too heterogeneous in terms of animal type, age, sex, interventionist strategy, and duration. The methods using bisphosphonates to treat ONFH also varied, including different bisphosphonate types, administration approaches, dosage, and durations, which may have influenced the outcomes. In summary, we observed improvement of the structural changes in terms of bone architecture and BV, but whether it could treat the ONFH in the animal model remains difficult to judge based on our outcomes alone.

Translating the animal results into clinical outcomes is always not easy, as discordant findings are usually present^[@CR46],[@CR47]^. Although heterogeneous animal models suggest the improvement of some bone morphology in this meta-analysis, this is not supported by pooled clinical studies, which showed no statistical differences in pain improvement, complications, or the need for THR. In fact, the clinical studies also showed high heterogeneity, including different bisphosphonate drugs, administration approaches, and combination with many other procedures, all of which may contribute to different outcomes present in those studies and also influence the pooled outcomes in this meta-analysis. Selection bias in terms of patient case mix, sample bias, publication bias, or unintended bias due to the interpretation of post-randomization events could also have changed the outcomes^[@CR46]^.

However, the obviously discordant findings in animal and human studies were still associated with some reasons. Animals and humans have different sensitivities to bisphosphonates. Animals were usually given adequate treatment doses throughout life, whereas humans were usually given low doses. It is easier to analyze the femoral head in animal models, both with radiographic films and specimen experiments. We only needed to analyze the desired outcomes while ignoring many other adverse events in animals. When we evaluated the patients, it was not until the femoral head had collapsed that we could obtain samples after the THA surgery, which means that the analytical methods were completely different and an effective evaluation method is lacking for human subjects. Besides, medication use in humans considers more consideration of safety, complications, and the overall body condition, all factors of which made the process differ from that of the animal experiment. More importantly, a poor methodology, publication bias, and inadequate animal models that simply do not reflect human disease are to blame for the discordant findings. Last but not least, it is difficult to know whether animal studies face similar problems regarding trial design. Clinical trials are usually powered to predict the number of patients likely to generate a statistical difference for the primary population. Additionally, to eliminate bias, patients are randomized and treatments are administered blindly by the researcher. In contrast, animal experiments are unlikely to be powered (usually concentrating on a static number per group according to laboratory preference) and rarely report crucial experimental design factors such as randomization and blinding^[@CR46]^. To this end, the lack of bias elimination in preclinical studies is thought to contribute to a five-fold likelihood of showing a beneficial therapeutic effect^[@CR48]^. Thus, using standardized animal models and standardized experiment methods may eliminate some of the differences between animal and human studies, enabling a greater degree of translation.

Conclusion {#Sec14}
==========

Bisphosphonates could improve bone architecture and BV in animal studies, but those results did not translate into either symptomatology or end-stage complications and management in the human studies. This might suggest that poor methodology, publication bias, and inadequate animal models that simply do not reflect human disease are to blame for the discordant findings. Thus, systematic reviews of animal studies are needed to ensure that the findings will be relevant to the design of clinical trials, while the use of standardized animal models and standardized experiment methods may eliminate some of the differences between animal and human studies to enable a greater degree of translation.
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